Related Experiment Video
Updated: Aug 5, 2025
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Dynamics of Hepatitis B Virus Covalently Closed Circular DNA: A Mini-Review
1Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing 400016, China.
Insights
Eradicating hepatitis B virus cccDNA requires understanding its half-life, influenced by host cell turnover and therapy. This review analyzes factors affecting cccDNA decay and proposes strategies for chronic hepatitis B treatment.
Area of Science:
- Hepatology
- Virology
- Molecular Biology
Background:
- Chronic hepatitis B (CHB) therapy aims to eliminate cccDNA, the viral DNA form persisting in hepatocytes.
- Understanding cccDNA dynamics, particularly its half-life, is crucial for developing effective CHB treatment strategies.
- cccDNA half-life is not an intrinsic property but reflects host cell factors and viral clearance mechanisms.
Purpose of the Study:
- To analyze key factors influencing cccDNA half-life in CHB.
- To identify research gaps concerning cccDNA decay mechanisms.
- To explain discrepancies in cccDNA half-life observed during nucleot(s)ide analog (NUC) therapy.
Main Methods:
- Literature review and analysis of existing data on cccDNA dynamics.
- Examination of host cell factors, including hepatocyte turnover and noncytopathic effects.
- Evaluation of NUC therapy's impact on cccDNA pool decline.
Main Results:
- cccDNA decay is primarily driven by hepatocyte turnover and noncytopathic effects.
- Observed discrepancies in cccDNA half-life exist between short-term and long-term NUC treatments.
- Multi-phasic decline patterns of cccDNA during NUC therapy require further investigation.
Conclusions:
- Hepatocyte lifespan significantly impacts cccDNA half-life, often more than cccDNA intrinsic properties.
- Further research is needed to elucidate the complex factors governing cccDNA decay.
- A framework based on cccDNA dynamics can guide the development of novel anti-HBV strategies.
Abstract:
Eradication of cccDNA is an ideal goal of chronic hepatitis B (CHB) therapy. Understanding the changes in the cccDNA pool during therapy provides a basis for developing CHB treatment strategies. On the other hand, the shift in the balance of the cccDNA pool following therapies allowed researchers to investigate the dynamics of cccDNA. Central to the description of cccDNA dynamics is a parameter called cccDNA half-life. CccDNA half-life is not an intrinsic property of cccDNA molecules, but a description of an observed phenomenon characterized by cccDNA pool decline. Since cccDNA has to be in the nuclei of host cells to function, the half-life of cccDNA is determined by the state and destiny of the host cells. The major factors that drive cccDNA decay include noncytopathic effects and hepatocyte turnover (death and division). In some cases, the determining factor is not the half-life of cccDNA itself, but rather the half-life of the hepatocyte. The main purpose of this review is to analyze the major factors affecting cccDNA half-life and determine the areas requiring further study. In addition, the discrepancy in cccDNA half-life between short-term and long-term nucleot(s)ide analog (NUC) therapy was reported. Hypotheses were proposed to explain the multi-phasic decline of cccDNA during NUC therapy, and a framework based on cccDNA dynamics was suggested for the consideration of various anti-HBV strategies.
